Pharmacy Policies

Navigate directly to a letter:

5
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
V
W
X

5
- 5HT3 RA, NK1 RA.pdf
Back to top
A
- Adakveo.pdf
- Adzynma.pdf
- Agents to Treat Gaucher Disease.pdf
- Alpha-1 Proteinase Inhibitors.pdf
- Amtagvi.pdf
- Anti-CD19 CAR-T Immunotherapies.pdf
- Anti-FGF23 Monoclonal Antibodies.pdf
- Antisense Oligonucleotides for DMD.pdf
Back to top
B
- BCMA Directed CAR T-Cell Therapy.pdf
- Benlysta.pdf
- Blincyto.pdf
- Botulinum Toxins A B.pdf
- Brineura.pdf
Back to top
C
- CGRP for Headache Prevention.pdf
- CNS Agents MS Legacy.pdf
- Cardiovascular Agents Pulmonary Arterial Hypertension.pdf
- Chelating Agents.pdf
- Complement Inhibitors.pdf
Back to top
D
- Dendritic Cell Tumor Peptide Immunotherapy.pdf
- Dose Rounding Limit Exception Criteria.pdf
Back to top
E
- Emergency Use Authorization (EUA) Drugs Products for COVID-19.pdf
- Enzyme replacement therapy for ASMD (Xenpozyme).pdf
- Epidermolysis Bullosa Agents.pdf
- Erythropoiesis-Stimulating Agents.pdf
Back to top
F
- Fecal Microbiota.pdf
Back to top
G
- GNRH Agonists.pdf
- Generalized Pustular Psoriasis (GPP) Agents.pdf
Back to top
H
- HIF-PH Inhibitors.pdf
- Hyaluronic Acid Derivatives.pdf
- Hydroxyprogesterone (generic Delalutin).pdf
Back to top
I
- Immune Globulins.pdf
- Immunomodulator Agents Systemic Inflammatory Disease.pdf
- Injectable Bone Modifying Oncology.pdf
- Insulin-Like Growth Factor-1 Receptor (Igf-1r) Antagonists For Thyroid Eye Disease.pdf
Back to top
K
- Kisunla-05052025.pdf
Back to top
L
- Lamzede-05072025.pdf
- Lenmeldy.pdf
- Leqembi.pdf
- Leqvio.pdf
Back to top
M
- Medication without specific criteria.pdf
- Mucopolysaccharidosis II (Hunter Syndrome) Agents.pdf
- Mucopolysaccharidosis VI Agents.pdf
- Myasthenia Gravis Agents.pdf
Back to top
N
- Natriuretic Peptides for Achondroplasia.pdf
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents.pdf
Back to top
O
- Off-Label Uses Criteria.pdf
- Omisirge.pdf
- Oncology.pdf
Back to top
P
- Palynziq.pdf
- Peanut Allergy Immunotherapy Agents.pdf
- Pompe Disease Agents.pdf
- Primary Hemophagocytic Lymphohistiocytosis (HLH) Agents.pdf
- Primary Hyperoxaluria Agents.pdf
Back to top
Q
- Qalsody.pdf
Back to top
R
- Radicava.pdf
- Reblozyl.pdf
- Respiratory Agents Monoclonal Antibodies-Anti-IL Anti-IgE.pdf
- Rituximab.pdf
- Rytelo.pdf
Back to top
S
- SMN2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy (SMA).pdf
- Somatostatin Analogs and Growth Hormone Receptor Antagonists.pdf
- Spravato.pdf
- Synagis.pdf
Back to top
T
- Transthyretin-mediated Amyloidosis Agents.pdf
- Treatments for Plasminogen Deficiency Type 1 (PLD1).pdf
- Type I Interferon (IFN) Receptor Antagonist.pdf
- Tzield.pdf
Back to top
V
- Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ophthalmic Conditions.pdf
- Veopoz.pdf
- Vimizim.pdf
Back to top
W
- White Blood Cell Stimulators.pdf
Back to top
X
- Xolremdi.pdf
Back to top